Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus ErythematosusGINZLER, Ellen M; WALLACE, Daniel J; FREIMUTH, William W et al.Journal of rheumatology. 2014, Vol 41, Num 2, pp 300-309, issn 0315-162X, 10 p.Article

2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid ArthritisSINGH, Jasvinder A; FURST, Daniel E; BRIDGES, S. Louis et al.Arthritis care and research. 2012, Vol 64, Num 5, pp 625-639, issn 0893-7524, 15 p.Article

A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients With Systemic Lupus ErythematosusFURIE, Richard; PETRI, Michelle; STOHL, William et al.Arthritis and rheumatism. 2011, Vol 63, Num 12, pp 3918-3930, issn 0004-3591, 13 p.Article

American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid ArthritisSAAG, Kenneth G; GIM GEE TENG; OUTMAN, Ryan et al.Arthritis care and research. 2008, Vol 59, Num 6, pp 762-784, issn 0893-7524, 23 p.Article